Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

  1. Chappell, K.J.
  2. Mordant, F.L.
  3. Li, Z.
  4. Wijesundara, D.K.
  5. Ellenberg, P.
  6. Lackenby, J.A.
  7. Cheung, S.T.M.
  8. Modhiran, N.
  9. Avumegah, M.S.
  10. Henderson, C.L.
  11. Hoger, K.
  12. Griffin, P.
  13. Bennet, J.
  14. Hensen, L.
  15. Zhang, W.
  16. Nguyen, T.H.O.
  17. Marrero-Hernandez, S.
  18. Selva, K.J.
  19. Chung, A.W.
  20. Tran, M.H.
  21. Tapley, P.
  22. Barnes, J.
  23. Reading, P.C.
  24. Nicholson, S.
  25. Corby, S.
  26. Holgate, T.
  27. Wines, B.D.
  28. Hogarth, P.M.
  29. Kedzierska, K.
  30. Purcell, D.F.J.
  31. Ranasinghe, C.
  32. Subbarao, K.
  33. Watterson, D.
  34. Young, P.R.
  35. Munro, T.P.
  36. Mostra tots els autors/es +
Revista:
The Lancet Infectious Diseases

ISSN: 1474-4457,  1473-3099

Any de publicació: 2021

Volum: 21

Número: 10

Pàgines: 1383-1394

Tipus: Article

DOI: 10.1016/S1473-3099(21)00200-0 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus